Sinovac Biotech Ltd., a China-based vaccine manufacturer, has received GMP certification from the China State Food and Drug Administration (SFDA) for mumps vaccine production plant at its Sinovac Dalian facility. The company obtained the production license from the SFDA for its mumps vaccine in December 2011. Sinovac anticipates commercial production of the vaccine in 3Q12 and is on track to launch the vaccine in China following the batch release process.
 
Mr. Weidong Yin, chairman, president and chief executive of Sinovac, said, “Obtaining GMP certification for the mumps vaccine production facility is a significant milestone as we advance our development pipeline and expand our portfolio of commercialized vaccines. We are poised to leverage our established sales and marketing team and distribution network that covers over 1,000 clients at Centers of Disease Control and Points of Vaccination across China. The commercialization of mumps vaccine is a testament to our capabilities to develop additional live attenuated vaccines. Commercial production of the mumps vaccine will commence immediately and we anticipate launching the vaccine either later this year or early next year following the batch release process.”